Sponsor Pipeline

Mirati Therapeutics Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
9
Active Trials
3
Recruiting
4
Phase 3
3
Disease Areas
6
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-15 NCT05853575
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
date change Primary completion moved earlier: 2026-11-30 -> 2026-10-30
2026-08-12 NCT04685135
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small…
Trial sites expanded: 343 -> 380 locations
2026-08-12 NCT04685135
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small…
date change Completion pushed: 2026-07-02 -> 2026-10-30
2026-08-05 NCT05853575
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
date change Primary completion pushed: 2026-07-30 -> 2026-11-30
2026-08-05 NCT05853575
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
date change Completion pushed: 2026-07-30 -> 2026-11-30
2026-07-30 NCT03785249
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
date change Primary completion moved earlier: 2026-12-31 -> 2026-06-23
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-07-23 NCT07723118 A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib… Phase 1 Not Yet Recruiting
Active Trials by Phase
Phase 3
3
Phase 2/3
1
Phase 2
3
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06875310 A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab… Carcinoma, Non-Small-Cell Lung Recruiting
NCT04793958 Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced… Advanced Colorectal Cancer Active, Not Recruiting
NCT04685135 Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small… Metastatic Non Small Cell Lung Cancer Active, Not Recruiting
Phase 2/3
NCT04613596 Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase… Advanced Non-Small Cell Lung Cancer Recruiting
Phase 2
NCT07415031 A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in… Solid Tumors Recruiting
NCT05609578 Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C… Advanced NSCLC Active, Not Recruiting
NCT05853575 Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Advanced Cancer Active, Not Recruiting
Phase 1/2
NCT03785249 Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Advanced Cancer Active, Not Recruiting
Phase 1
NCT07723118 A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib… Healthy Participants Not Yet Recruiting
Disease Areas
Get alerts when Mirati Therapeutics Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free